NSCLC patients receiving TRT showed a significant decrease in sPD-L1 at week 2 and week 4 compared to baseline levels; however, sPD-L1 levels returned to baseline levels post-TRT (182). The gene discussed is SPDL1; the disease is non-small cell lung carcinoma.